Systolic heart failure
diseaseOn this page
Summary
Systolic heart failure (MONDO:0006993) is a disease with 5 cohort genes (15 GWAS associations across 5 studies) and 55 clinical trials. Top therapeutic interventions include cephalexin anhydrous, ferric carboxymaltose, and bacitracin.
At a glance
- Cohort genes: 5
- GWAS associations: 15
- ClinVar variants: 5
- Clinical trials: 55
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | systolic heart failure |
| Mondo ID | MONDO:0006993 |
| EFO | EFO:1001207 |
| MeSH | D054143 |
| DOID | DOID:9651 |
| SNOMED CT | 417996009 |
| UMLS | C1135191 |
| MedGen | 210050 |
| MedDRA | 10074631 |
| Is cancer (heuristic) | no |
Data availability: 5 ClinVar variants · 15 GWAS associations (5 studies).
Disease family
Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › heart disorder › heart failure › congestive heart failure › systolic heart failure
Related subtypes (4): rheumatic congestive heart failure, cor pulmonale, diastolic heart failure, left ventricular failure
Genetics & variants
GWAS landscape
15 GWAS associations across 5 studies. Top hits map to 7 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs3176326 | 7e-34 | CDKN1A | G | 0.13 |
| rs10455872 | 9e-21 | LPA | A | 0.14 |
| rs4977575 | 6e-19 | CDKN2B-AS1 | C | 0.07 |
| chr10:121422836 | 1e-18 | G | 0.09 | |
| rs11642015 | 2e-18 | FTO | C | 0.07 |
| rs945425 | 2e-17 | CLCNKA | T | 0.07 |
| rs1421085 | 5e-16 | FTO | T | 0.07 |
| rs17617337 | 2e-14 | BAG3 | C | 0.08 |
| chr1:16304398 | 4e-14 | G | 0.07 | |
| rs56968346 | 9e-13 | MAP3K7CL | C | 0.07 |
| rs3807132 | 1e-12 | CCDC136 - FLNC | T | 0.08 |
| chr21:30535302 | 9e-12 | C | 0.08 |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90475983 | Verma A | 2024 | 31,220 | 407,213 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90477961 | Verma A | 2024 | 9,104 | 109,632 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90480182 | Verma A | 2024 | 9,104 | 109,632 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90477960 | Verma A | 2024 | 2,652 | 56,189 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90482010 | Verma A | 2024 | 211 | 6,566 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 1 |
| Tier 4: intronic/intergenic | 11 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 12 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 0 |
| unknown | 0 |
Functional consequences
| Consequence | Count |
|---|---|
| intron_variant | 7 |
| unknown | 3 |
| regulatory_region_variant | 1 |
| intergenic_variant | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs3176326 | 6 | 36679512 | G>A | 0.203 | intron_variant | CDKN1A | 7e-34 | Tier 4: intronic/intergenic |
| rs10455872 | 6 | 160589086 | A>G | 0.069 | intron_variant | LPA | 9e-21 | Tier 4: intronic/intergenic |
| rs4977575 | 9 | 22124745 | C>G,T | 0.496 | regulatory_region_variant | CDKN2B-AS1 | 6e-19 | Tier 3: regulatory |
| chr10:121422836 | 0.21 | 1e-18 | Tier 4: intronic/intergenic | |||||
| rs11642015 | 16 | 53768582 | C>G,T | 0.403 | intron_variant | FTO | 2e-18 | Tier 4: intronic/intergenic |
| rs945425 | 1 | 16021917 | T>A,C | 0.315 | intergenic_variant | CLCNKA | 2e-17 | Tier 4: intronic/intergenic |
| rs1421085 | 16 | 53767042 | T>C | 0.333 | intron_variant | FTO | 5e-16 | Tier 4: intronic/intergenic |
| rs17617337 | 10 | 119667372 | C>T | 0.166 | intron_variant | BAG3 | 2e-14 | Tier 4: intronic/intergenic |
| chr1:16304398 | 0.32 | 4e-14 | Tier 4: intronic/intergenic | |||||
| rs56968346 | 21 | 29167844 | C>G,T | 0.204 | intron_variant | MAP3K7CL | 9e-13 | Tier 4: intronic/intergenic |
| rs3807132 | 7 | 128829430 | T>C | 0.136 | intron_variant | CCDC136 - FLNC | 1e-12 | Tier 4: intronic/intergenic |
| chr21:30535302 | 0.15 | 9e-12 | Tier 4: intronic/intergenic |
ClinVar germline variants
5 retrieved; paginated sample, class counts are floors:
2 benign/likely benign, 2 conflicting classifications of pathogenicity, 1 benign
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 45639 | NM_014391.3(ANKRD1):c.827C>T (p.Ala276Val) | ANKRD1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 47210 | NM_001267550.2(TTN):c.5668C>T (p.Arg1890Cys) | TTN | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 36010 | NM_001943.5(DSG2):c.1543G>A (p.Val515Ile) | DSG2 | Benign/Likely benign | criteria provided, multiple submitters, no conflicts |
| 44963 | NM_004415.4(DSP):c.8300C>A (p.Thr2767Asn) | DSP | Benign/Likely benign | criteria provided, multiple submitters, no conflicts |
| 46411 | NM_001386795.1(DTNA):c.1438C>A (p.Pro480Thr) | DTNA | Benign | criteria provided, multiple submitters, no conflicts |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 0 · Orphanet: 30 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| TTN | Orphanet:140922 | Titin-related limb-girdle muscular dystrophy R10 |
| TTN | Orphanet:154 | Familial isolated dilated cardiomyopathy |
| TTN | Orphanet:169186 | Autosomal recessive centronuclear myopathy |
| TTN | Orphanet:178464 | Hereditary myopathy with early respiratory failure |
| TTN | Orphanet:289377 | Early-onset myopathy with fatal cardiomyopathy |
| TTN | Orphanet:293888 | Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant |
| TTN | Orphanet:293899 | Inherited isolated arrhythmogenic ventricular dysplasia, biventricular variant |
| TTN | Orphanet:293910 | Inherited isolated arrhythmogenic cardiomyopathy, dominant-right variant |
| TTN | Orphanet:324604 | Classic multiminicore myopathy |
| TTN | Orphanet:334 | Hereditary atrial fibrillation |
| TTN | Orphanet:466921 | Childhood-onset progressive contractures-limb-girdle weakness-muscle dystrophy syndrome |
| TTN | Orphanet:609 | Tibial muscular dystrophy |
| TTN | Orphanet:707983 | Early-onset autosomal recessive TTN-related distal myopathy |
| ANKRD1 | Orphanet:154 | Familial isolated dilated cardiomyopathy |
| DSG2 | Orphanet:154 | Familial isolated dilated cardiomyopathy |
| DSG2 | Orphanet:293888 | Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant |
| DSG2 | Orphanet:293899 | Inherited isolated arrhythmogenic ventricular dysplasia, biventricular variant |
| DSG2 | Orphanet:293910 | Inherited isolated arrhythmogenic cardiomyopathy, dominant-right variant |
| DSP | Orphanet:154 | Familial isolated dilated cardiomyopathy |
| DSP | Orphanet:158687 | Lethal acantholytic erosive disorder |
| DSP | Orphanet:2032 | Idiopathic pulmonary fibrosis |
| DSP | Orphanet:293165 | Skin fragility-woolly hair-palmoplantar keratoderma syndrome |
| DSP | Orphanet:293888 | Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant |
| DSP | Orphanet:293899 | Inherited isolated arrhythmogenic ventricular dysplasia, biventricular variant |
| DSP | Orphanet:293910 | Inherited isolated arrhythmogenic cardiomyopathy, dominant-right variant |
| DSP | Orphanet:369992 | Severe dermatitis-multiple allergies-metabolic wasting syndrome |
| DSP | Orphanet:476096 | Erythrokeratodermia-cardiomyopathy syndrome |
| DSP | Orphanet:50942 | Striate palmoplantar keratoderma |
| DSP | Orphanet:65282 | Carvajal syndrome |
| DTNA | Orphanet:54260 | Left ventricular noncompaction |
Cohort genes → proteins
5 cohort genes, 5 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 5 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| TTN | HGNC:12403 | ENSG00000155657 | Q8WZ42 | Titin | clinvar |
| ANKRD1 | HGNC:15819 | ENSG00000148677 | Q15327 | Ankyrin repeat domain-containing protein 1 | clinvar |
| DSG2 | HGNC:3049 | ENSG00000046604 | Q14126 | Desmoglein-2 | clinvar |
| DSP | HGNC:3052 | ENSG00000096696 | P15924 | Desmoplakin | clinvar |
| DTNA | HGNC:3057 | ENSG00000134769 | Q9Y4J8 | Dystrobrevin alpha | clinvar |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| TTN | Titin | Key component in the assembly and functioning of vertebrate striated muscles. |
| ANKRD1 | Ankyrin repeat domain-containing protein 1 | May play an important role in endothelial cell activation. |
| DSG2 | Desmoglein-2 | A component of desmosome cell-cell junctions which are required for positive regulation of cellular adhesion. |
| DSP | Desmoplakin | A component of desmosome cell-cell junctions which are required for positive regulation of cellular adhesion. |
| DTNA | Dystrobrevin alpha | May be involved in the formation and stability of synapses as well as being involved in the clustering of nicotinic acetylcholine receptors. |
Protein-family classification
Druggable: 1 · Difficult: 3 · Unknown: 1 · Druggable fraction: 0.2
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Scaffold/PPI | 2 | 6.9× | 0.119 |
| Kinase | 1 | 5.5× | 0.336 |
| Transcription factor | 1 | 1.6× | 0.634 |
| Other/Unknown | 1 | 0.4× | 0.983 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| TTN | Kinase | yes | 2.7.11.1 | Prot_kinase_dom, Ig_sub2, Ig_sub |
| ANKRD1 | Scaffold/PPI | no | Ankyrin_rpt, Ankyrin_rpt-contain_sf | |
| DSG2 | Other/Unknown | no | Cadherin-like_dom, Desmosomal_cadherin, Cadherin-like_sf | |
| DSP | Scaffold/PPI | no | Plectin_repeat, SH3_domain, Spectrin/alpha-actinin | |
| DTNA | Transcription factor | no | Znf_ZZ, EF-hand-dom_pair, EF-hand_dom_typ1 |
Expression context
Cohort genes with no expression data: 0.
5 cohort genes are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 5 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| biceps brachii | 1 |
| gluteal muscle | 1 |
| skeletal muscle tissue of biceps brachii | 1 |
| apex of heart | 1 |
| cardiac atrium | 1 |
| right atrium auricular region | 1 |
| colonic mucosa | 1 |
| jejunal mucosa | 1 |
| mucosa of sigmoid colon | 1 |
| hair follicle | 1 |
| skin of hip | 1 |
| upper leg skin | 1 |
| C1 segment of cervical spinal cord | 1 |
| globus pallidus | 1 |
| medial globus pallidus | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| TTN | 223 | broad | marker | biceps brachii, gluteal muscle, skeletal muscle tissue of biceps brachii |
| ANKRD1 | 155 | ubiquitous | marker | apex of heart, right atrium auricular region, cardiac atrium |
| DSG2 | 238 | ubiquitous | marker | mucosa of sigmoid colon, colonic mucosa, jejunal mucosa |
| DSP | 253 | ubiquitous | marker | skin of hip, upper leg skin, hair follicle |
| DTNA | 266 | ubiquitous | marker | medial globus pallidus, globus pallidus, C1 segment of cervical spinal cord |
Protein interactions among cohort
Intra-cohort edges: 2.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| TTN | 4,237 |
| DSP | 2,897 |
| ANKRD1 | 2,441 |
| DSG2 | 2,033 |
| DTNA | 1,738 |
Intra-cohort edges
| A | B | Sources |
|---|---|---|
| ANKRD1 | TTN | biogrid_interaction, string_interaction |
| DSG2 | DSP | string_interaction |
Structural data
PDB: 4 · AlphaFold-only: 1 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| TTN | Q8WZ42 | 64 |
| DSG2 | Q14126 | 12 |
| DSP | P15924 | 4 |
| DTNA | Q9Y4J8 | 1 |
AlphaFold-only cohort genes (top 30 by pLDDT)
| Symbol | UniProt | pLDDT |
|---|---|---|
| ANKRD1 | Q15327 | 82.64 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 16. Enrichment computed across 5 evidence-associated genes (5 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 5 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| Apoptotic cleavage of cell adhesion proteins | 2 | 415.3× | 1e-04 | DSG2, DSP |
| Formation of the cornified envelope | 2 | 35.1× | 0.010 | DSG2, DSP |
| Keratinization | 2 | 22.3× | 0.017 | DSG2, DSP |
| Striated Muscle Contraction | 1 | 61.7× | 0.044 | TTN |
| Formation of the dystrophin-glycoprotein complex (DGC) | 1 | 61.7× | 0.044 | DTNA |
| RND1 GTPase cycle | 1 | 53.1× | 0.044 | DSP |
| RND3 GTPase cycle | 1 | 51.9× | 0.044 | DSP |
| RHOG GTPase cycle | 1 | 29.7× | 0.060 | DSG2 |
| Regulation of lipid metabolism by PPARalpha | 1 | 28.2× | 0.060 | ANKRD1 |
| RAC2 GTPase cycle | 1 | 25.4× | 0.060 | DSG2 |
| RAC3 GTPase cycle | 1 | 23.8× | 0.060 | DSG2 |
| PPARA activates gene expression | 1 | 18.9× | 0.068 | ANKRD1 |
| Platelet degranulation | 1 | 17.6× | 0.068 | TTN |
| Metabolism of lipids | 1 | 6.3× | 0.170 | ANKRD1 |
| Neutrophil degranulation | 1 | 4.6× | 0.212 | DSP |
| Metabolism | 1 | 2.3× | 0.362 | ANKRD1 |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 5 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| bundle of His cell-Purkinje myocyte adhesion involved in cell communication | 2 | 963.0× | 7e-05 | DSG2, DSP |
| desmosome organization | 2 | 842.6× | 7e-05 | DSG2, DSP |
| cardiac muscle tissue morphogenesis | 2 | 561.7× | 8e-05 | TTN, ANKRD1 |
| regulation of ventricular cardiac muscle cell action potential | 2 | 561.7× | 8e-05 | DSG2, DSP |
| striated muscle contraction | 2 | 337.0× | 2e-04 | TTN, DTNA |
| sarcomere organization | 2 | 153.2× | 7e-04 | TTN, ANKRD1 |
| regulation of heart rate by cardiac conduction | 2 | 149.8× | 7e-04 | DSG2, DSP |
| positive regulation of protein secretion | 2 | 137.6× | 7e-04 | TTN, ANKRD1 |
| Purkinje myocyte development | 1 | 1685.2× | 0.005 | DSG2 |
| skeletal muscle myosin thick filament assembly | 1 | 1123.5× | 0.005 | TTN |
| sarcomerogenesis | 1 | 1123.5× | 0.005 | TTN |
| positive regulation of protein localization to cell-cell junction | 1 | 1123.5× | 0.005 | DSG2 |
| cell-cell adhesion | 2 | 40.6× | 0.005 | DSG2, DSP |
| negative regulation of endothelial cell differentiation | 1 | 674.1× | 0.007 | DSG2 |
| skeletal muscle thin filament assembly | 1 | 561.7× | 0.008 | TTN |
| phospholipase C/protein kinase C signal transduction | 1 | 561.7× | 0.008 | ANKRD1 |
| ventricular compact myocardium morphogenesis | 1 | 481.5× | 0.008 | DSP |
| detection of muscle stretch | 1 | 481.5× | 0.008 | TTN |
| protein localization to cell-cell junction | 1 | 374.5× | 0.009 | DSP |
| negative regulation of DNA biosynthetic process | 1 | 374.5× | 0.009 | ANKRD1 |
| cardiac muscle hypertrophy | 1 | 337.0× | 0.009 | TTN |
| negative regulation of inflammatory response to wounding | 1 | 337.0× | 0.009 | DSG2 |
| mesenchymal to epithelial transition | 1 | 306.4× | 0.010 | DSG2 |
| synaptic signaling | 1 | 306.4× | 0.010 | DTNA |
| obsolete protein kinase A signaling | 1 | 280.9× | 0.010 | TTN |
| peptide cross-linking | 1 | 280.9× | 0.010 | DSP |
| cardiac myofibril assembly | 1 | 259.3× | 0.010 | TTN |
| epithelial cell-cell adhesion | 1 | 240.7× | 0.010 | DSP |
| muscle filament sliding | 1 | 210.7× | 0.011 | TTN |
| mitotic chromosome condensation | 1 | 198.3× | 0.011 | TTN |
Therapeutics
Drugs indicated for this disease
0 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| HUMAN NEUREGULIN-1 RECOMBINANT (177-237) | Phase 3 (in late-stage trials) |
| Udenafil | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Ivabradine, Metformin, Niacin, Probenecid, Rifaximin.
Drug target analysis
Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 5
Druggability breadth: 2 of 5 evidence-associated genes (40%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| TTN | 0 | 0 |
| ANKRD1 | 0 | 0 |
| DSG2 | 0 | 0 |
| DSP | 0 | 0 |
| DTNA | 0 | 0 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 1.
Cohort genes with ChEMBL bioactivity (full, sorted by assay count)
| Symbol | Assays | Type breakdown |
|---|---|---|
| DSP | 2 | Binding:2 |
| TTN | 1 | Binding:1 |
Cohort enzymes (BRENDA EC)
| Symbol | EC numbers | Names |
|---|---|---|
| TTN | 2.7.11.1 | non-specific serine/threonine protein kinase |
Pharmacogenomics
Cohort genes with a PharmGKB record: 5; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 0 | |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 1 | TTN |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 4 | ANKRD1, DSG2, DSP, DTNA |
Undrugged target profiles
5 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| TTN | 1 | — |
| ANKRD1 | 0 | — |
| DSG2 | 0 | — |
| DSP | 2 | — |
| DTNA | 0 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 55.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 32 |
| PHASE4 | 8 |
| PHASE3 | 7 |
| PHASE2 | 3 |
| PHASE1 | 3 |
| PHASE2/PHASE3 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03984591 | PHASE4 | ENROLLING_BY_INVITATION | A Registry-based Cluster Randomized Trial to Compare the Effect of Spironolactone vs. Eplerenone on Clinical Outcomes in Patients With Symptomatic Systolic Heart Failure |
| NCT00348530 | PHASE4 | UNKNOWN | Carvedilol Versus Verapamil in Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy |
| NCT01765400 | PHASE4 | COMPLETED | Platelet Inhibition in Patients With Systolic Heart Failure |
| NCT02316743 | PHASE4 | UNKNOWN | Effects of Levothyroxine Supplementation in Patients With Systolic Heart Failure and Subclinical Hypothyroidism |
| NCT02903225 | PHASE4 | COMPLETED | Clinical Value of Heart Rate Variability Indexes to Predict Outcomes After Exercise Training in Chronic Heart Failure |
| NCT03036462 | PHASE4 | COMPLETED | Intravenous Iron in Patients With Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality |
| NCT03764722 | PHASE4 | UNKNOWN | Effectiveness of a Repetitive Use of 24-hour Levosimendan Infusions in Patients With Severe Systolic Heart Failure in Order to Prevent Rehospitalizations |
| NCT03871699 | PHASE4 | UNKNOWN | Ferric Carboximaltose on Intra-myocardial Iron Load in Patients With Heart Failure |
| NCT01362725 | PHASE2/PHASE3 | COMPLETED | Spinal Cord Stimulation For Heart Failure |
| NCT01439893 | PHASE3 | TERMINATED | Study of Efficacy on Cardiac Remodeling of Recombinant Human Neuregulin-1 in Stable Chronic Systolic Heart Failure Patients |
| NCT01639378 | PHASE3 | UNKNOWN | Renal Artery Denervation in Chronic Heart Failure Study |
| NCT01646515 | PHASE3 | TERMINATED | Udenafil Therapy to Improve Symptomatology, Exercise Tolerance and Hemodynamics in Patients With Chronic Systolic Heart Failure |
| NCT02188082 | PHASE2/PHASE3 | UNKNOWN | Clinical Trial of Systolic Heart Failure Treatment of IvabRadine Hemisulfate Sustained-release Tablets （FIRST） |
| NCT02809131 | PHASE3 | COMPLETED | Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections. |
| NCT03991000 | PHASE3 | TERMINATED | Iron in Patients With Cardiovascular Disease |
| NCT04468529 | PHASE3 | COMPLETED | Evaluate the Effect of Injectable Neucardin on the Cardiac Function of Subjects With Chronic Systolic Heart Failure |
| NCT05949801 | PHASE3 | COMPLETED | Evaluation of the Effect of Injectable Neucardin on Cardiac Function and Reversal Ventricular Remodeling in Patients With Chronic Systolic Heart Failure |
| NCT01814319 | PHASE2 | COMPLETED | Repurposing Probenecid as a Positive Inotrope for the Treatment of Heart Failure |
| NCT01935622 | PHASE2 | TERMINATED | Safety and Efficacy of Doxycycline in Patients With Non-Ischemic Cardiomyopathy |
| NCT02637167 | PHASE2 | UNKNOWN | GutHeart: Targeting Gut Microbiota to Treat Heart Failure |
| NCT01224899 | PHASE1 | COMPLETED | Surgical Sympathetic Blockade in Heart Failure |
| NCT03504891 | PHASE1 | UNKNOWN | Cardiac MRI for Optimal Heart Failure Outcomes With CRT Upgrades |
| NCT03534297 | PHASE1 | COMPLETED | Study of Dapansutrile Capsules in Heart Failure |
| NCT05230732 | Not specified | RECRUITING | Neuromodulation of Inflammation and Endothelial Function |
| NCT06671015 | Not specified | RECRUITING | A Trial Comparing High-Flow Nasal Cannula Versus Noninvasive Ventilation on Reintubation and Post-Extubation Respiratory Failure in High-Risk Patients With Systolic Heart Failure |
| NCT00709241 | Not specified | COMPLETED | Psychosocial Patterns and Prognosis in Patients With Heart Failure |
| NCT00833352 | Not specified | COMPLETED | Comparison of Right Ventricular Septal and Right Ventricular Apical Pacing in Patients Receiving a CRT-D Device |
| NCT00949676 | Not specified | UNKNOWN | DECIDE-HF: Heart Rate Variability in Heart Failure Patients |
| NCT01127334 | Not specified | WITHDRAWN | Pilot Study Using Echocardiography to Evaluate Patients With Heart Failure and Dyssynchrony Who Have a CRT-D Device |
| NCT01139697 | Not specified | COMPLETED | Hair Cortisol and Testosterone in Heart Failure |
| NCT01347567 | Not specified | COMPLETED | Heart Failure (HF) Outpatient Monitoring Evaluation (HOME) Study |
| NCT01566344 | Not specified | UNKNOWN | Reversal of Cardiomyopathy by Suppression of Frequent Premature Ventricular Complexes |
| NCT01640769 | Not specified | COMPLETED | Imaging Study of Allocation of Pacing Targets in Cardiac Resynchronization Therapy |
| NCT01653821 | Not specified | COMPLETED | Surgical Removal of Carotid Body in Patients With Systolic Heart Failure |
| NCT01735916 | Not specified | TERMINATED | MIRACLE EF Clinical Study |
| NCT01782677 | Not specified | COMPLETED | Bilateral Surgical Resection of Carotid Bodies in Patients With Systolic Heart Failure |
| NCT01932294 | Not specified | COMPLETED | Medical Arm of the Interagency Registry for Mechanically Assisted Circulatory Support |
| NCT02018497 | Not specified | UNKNOWN | Essential Hypotension and Allostasis Registry |
| NCT02026102 | Not specified | COMPLETED | A Pilot Trial of Patient Decision Aids for Implantable Cardioverter-Defibrillators (ICDs) |
| NCT02084992 | Not specified | COMPLETED | A Study of a Technology-enabled Disease Management Program to Reduce Hospitalizations for Heart Failure |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CEPHALEXIN ANHYDROUS | 4 | 3 |
| FERRIC CARBOXYMALTOSE | 4 | 2 |
| BACITRACIN | 4 | 1 |
| EPLERENONE | 4 | 1 |
| LEVOTHYROXINE | 4 | 1 |
| PROBENECID | 4 | 1 |
| RIFAXIMIN | 4 | 1 |
| SPIRONOLACTONE | 4 | 1 |
| VERAPAMIL | 4 | 1 |
| HUMAN NEUREGULIN-1 RECOMBINANT (177-237) | 3 | 2 |
| LEVOSIMENDAN | 3 | 1 |
| UDENAFIL | 3 | 1 |
| DAPANSUTRILE | 2 | 1 |
| DEXVERAPAMIL | 2 | 1 |
| CHEMBL1562223 | 0 | 1 |
| CHEMBL30458 | 0 | 1 |
| CHEMBL3764363 | 0 | 1 |
| CHEMBL4096945 | 0 | 1 |
| CHEMBL4209556 | 0 | 1 |
| CHEMBL4303306 | 0 | 1 |
Related Atlas pages
- Cohort genes: TTN, ANKRD1, DSG2, DSP, DTNA
- Drugs: Cephalexin, Ferric Carboxymaltose, Bacitracin, Eplerenone, Levothyroxine, Probenecid, Rifaximin, Spironolactone, Verapamil, HUMAN NEUREGULIN-1 RECOMBINANT (177-237), Levosimendan, Udenafil